Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity
Table 2
Case A
Case B
Case C
Diagnosis
t-AML*
AML
ALL
Age at first diagnosis
21
29
32
Date of first diagnosis
04/2007
05/2005
11/2010
Course of treatment
Induction
Cytarabine + idarubicin/HAM
Sequential HAM
None
(1) Allogeneic HSCT
08/07: allogeneic HSCT (MUD)
07/05: allogeneic HSCT (MRD)
02/12: Relapse incl. chloroma/CNS
01/09: relapse
Salvage therapies
Clofarabine
03/2009 Stem cell boost + GM-CSF
07/09 Relapse incl. chloroma
Cytarabine + gemtuzumab/ozogamicin
(2) Allogeneic HSCT
05/12: HLA haploidentical HSCT (sister)
08/09: HLA haploidentical HSCT + G-CSF (father)
Status at testing
03/13: Relapse
07/10: Relapse incl. chloroma, immunotherapy
First diagnosis
Therapy related AML after 8x BEACOPP for Hodgkin’s disease. Abbreviations: AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, MUD: matched unrelated donor, MRD: matched related donor, G-CSF/GM-CSF: granulocyte/granulocyte macrophage colony-stimulating factor, HAM: high dosed cytarabin/mitoxantron, CNS: central nervous system involvement.